# Early Recognition and Optimal Treatment of Delirium in Patients With Advanced Cancer

> **NCT01539733** · NA · COMPLETED · sponsor: **Amsterdam UMC, location VUmc** · enrollment: 101 (actual)

## Conditions studied

- Delirium
- Advanced Cancer

## Interventions

- **DRUG:** Olanzapine
- **DRUG:** Haloperidol

## Key facts

- **NCT ID:** NCT01539733
- **Lead sponsor:** Amsterdam UMC, location VUmc
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2017-04
- **Final completion:** 2017-04
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2017-04-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01539733

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01539733, "Early Recognition and Optimal Treatment of Delirium in Patients With Advanced Cancer". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT01539733. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*